GMED Add to watchlist $94.55 0.39 (-0.41%) Last updated: Apr 16, 2026 02:57
52-Week Range
$94.55
$51.79 $94.55 $101.40

Fundamentals Overview

Globus Medical, Inc. is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 24.1 PEG 0.06 P/B 2.79 P/S 4.35

Intrinsic value (DCF)

-59.3% downside vs price

Profitability

Net margin 18.3%

Risk (Beta)

1.09 — in line vol

Earnings & growth

EPS $3.92 Rev +7.5% Profit +18.2% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 50% confidence Risk: Moderate Volatility — Beta 1.09. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: A · Sentiment improving (3 upgrades) · 3M vs Healthcare sector: +9.2%

Pressures (Sell):

DCF 59.3% downside vs price

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$12.79B
P/E (TTM)
24.12
EPS (TTM)
$3.92
Dividend Yield
N/A
52-Week Range
$51.79 - $101.40
Volume vs Avg
N/A
Beta
1.09

About

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic s...
Sector: Healthcare
Headquarters: US
Employees: 5,300
IPO Date: Aug 2012
Beta: 1.09 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 10, Hold: 5, Market Perform: 2, Neutral: 1, Outperform: 3, Overweight: 9.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $38.49; current price is $94.55. That’s a -59.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 24.12
DCF value (model) $38.49 (-59.3% vs price)
PEG (TTM) 0.06
P/B (TTM) 2.79
P/S (TTM) 4.35
P/FCF (TTM) 22.1
Liquidity & enterprise
Current Ratio (TTM) 4.26
Quick Ratio (TTM) 2.74
Cash Ratio (TTM) 1.06
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 18.3%
Gross margin (TTM) 67.41%
Operating margin (TTM) 16.33%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for GMED.

Analyst Sentiment at a Glance

A Sentiment Improving
Buy 10Hold 5Market Perform 2Neutral 1Outperform 3Overweight 9
3 upgrades, 1 downgrade
Price Target Consensus
Current $94.55
Median $112.00
Consensus $104.00
Low consensus $64.00
High consensus $115.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Wells Fargo maintain Overweight Overweight 2026-02-26
Barclays maintain Overweight Overweight 2026-02-25
Needham maintain Buy Buy 2026-02-25
Needham upgrade Hold Buy 2026-01-30
Canaccord Genuity maintain Buy Buy 2026-01-09
Piper Sandler maintain Overweight Overweight 2026-01-08
RBC Capital maintain Outperform Outperform 2025-12-17
Canaccord Genuity maintain Buy Buy 2025-12-17
Morgan Stanley maintain Overweight Overweight 2025-12-02
Truist Securities maintain Buy Buy 2025-11-18
Barclays maintain Overweight Overweight 2025-11-10
B of A Securities upgrade Neutral Buy 2025-11-07
RBC Capital maintain Outperform Outperform 2025-11-07
Wells Fargo maintain Overweight Overweight 2025-11-07
Truist Securities upgrade Hold Buy 2025-11-07
RBC Capital maintain Outperform Outperform 2025-10-10
Wells Fargo maintain Overweight Overweight 2025-08-08
Canaccord Genuity maintain Buy Buy 2025-07-22
Needham maintain Hold Hold 2025-07-21
Morgan Stanley maintain Overweight Overweight 2025-07-15
JMP Securities maintain Market Perform Market Perform 2025-05-27
BTIG downgrade Buy Neutral 2025-05-27
Truist Securities maintain Hold Hold 2025-05-12
BTIG maintain Buy Buy 2025-05-09
Piper Sandler maintain Overweight Overweight 2025-05-09
Truist Securities maintain Hold Hold 2025-04-11
BTIG maintain Buy Buy 2025-04-09
Needham maintain Hold Hold 2025-03-18
Truist Securities maintain Hold Hold 2025-03-18
Citizens Capital Markets maintain Market Perform Market Perform 2025-02-24